United States: These 33 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: uridine triacetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

VISTOGARD is a drug marketed by Wellstat Therap. There are two patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

Generic name: uridine triacetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

XURIDEN is a drug marketed by Wellstat Therap. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

Generic name: riboflavin 5'-phosphate sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 15, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PHOTREXA is a drug marketed by Glaukos.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

See drug price trends for PHOTREXA.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Generic name: plerixafor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2023
Generic Entry Controlled by: United States Patent Patent 7,897,590

MOZOBIL is a drug marketed by Genzyme. There are two patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has fifty-two patent family members in twenty-seven countries. There has been litigation on patents covering MOZOBIL

See drug price trends for MOZOBIL.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the plerixafor profile page.

Generic name: budesonide; formoterol fumarate; glycopyrrolate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 23, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BREZTRI AEROSPHERE is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug.

This drug has two hundred and one patent family members in thirty-three countries.

The generic ingredient in BREZTRI AEROSPHERE is budesonide; formoterol fumarate; glycopyrrolate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the budesonide; formoterol fumarate; glycopyrrolate profile page.

Generic name: cysteamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 19, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

CYSTADROPS is a drug marketed by Recordati Rare.

This drug has two hundred and one patent family members in thirty-three countries.

See drug price trends for CYSTADROPS.

The generic ingredient in CYSTADROPS is cysteamine hydrochloride. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 24, 2023
Generic Entry Controlled by: United States Patent Patent 7,655,630

VYVANSE is a drug marketed by Takeda Pharms Usa. There are eighteen patents protecting this drug and one Paragraph IV challenge. Eight tentatively approved generics are ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-seven countries. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. One supplier is listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

Generic name: telbivudine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 11, 2023
Generic Entry Controlled by: United States Patent Patent 6,569,837

TYZEKA is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eleven patent family members in seven countries.

The generic ingredient in TYZEKA is telbivudine. There are two drug master file entries for this API. Additional details are available on the telbivudine profile page.

Generic name: anidulafungin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ERAXIS is a drug marketed by Vicuron Holdings.

This drug has eleven patent family members in seven countries.

See drug price trends for ERAXIS.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the anidulafungin profile page.

Generic name: pazopanib hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 19, 2023
Generic Entry Controlled by: United States Patent Patent 7,105,530

VOTRIENT is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

See drug price trends for VOTRIENT.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pazopanib hydrochloride profile page.

Generic name: magnesium sulfate; potassium chloride; sodium sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUTAB (COPACKAGED) is a drug marketed by

This drug has forty patent family members in twenty-five countries.

The generic ingredient in SUTAB (COPACKAGED) is magnesium sulfate; potassium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the magnesium sulfate; potassium chloride; sodium sulfate profile page.

Generic name: levalbuterol tartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2023
Generic Entry Controlled by: United States Patent Patent 8,765,153

XOPENEX HFA is a drug marketed by Lupin. There are two patents protecting this drug.

This drug has thirty-six patent family members in eighteen countries. There has been litigation on patents covering XOPENEX HFA

See drug price trends for XOPENEX HFA.

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. There are nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the levalbuterol tartrate profile page.

Generic name: thalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 09, 2023
Generic Entry Controlled by: United States Patent Patent 7,230,012

THALOMID is a drug marketed by Celgene. There is one patent protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in nineteen countries. There has been litigation on patents covering THALOMID

See drug price trends for THALOMID.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the thalidomide profile page.

Generic name: prucalopride succinate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MOTEGRITY is a drug marketed by Takeda Pharms Usa.

This drug has twenty-nine patent family members in nineteen countries.

See drug price trends for MOTEGRITY.

The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this generic product. Additional details are available on the prucalopride succinate profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 16, 2023
Generic Entry Controlled by: United States Patent Patent 6,562,861

RAPIVAB is a drug marketed by Biocryst. There are three patents protecting this drug.

This drug has seventy patent family members in twenty-eight countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 18, 2024
Generic Entry Controlled by: United States Patent Patent 9,328,133

AURYXIA is a drug marketed by Keryx Biopharms. There are fifteen patents protecting this drug.

This drug has one hundred and thirty-seven patent family members in twenty-six countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: esketamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SPRAVATO is a drug marketed by Janssen Pharms. There are six patents protecting this drug.

This drug has forty-one patent family members in nineteen countries.

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this generic product. Additional details are available on the esketamine hydrochloride profile page.

Generic name: bupivacaine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There are eight patents protecting this drug.

This drug has five patent family members in four countries. There has been litigation on patents covering EXPAREL

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. There are twelve drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the bupivacaine profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2024
Generic Entry Controlled by: United States Patent Patent 11,278,544

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-nine patent family members in forty-three countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: spinosad
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NATROBA is a drug marketed by Parapro Llc. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-eight countries.

See drug price trends for NATROBA.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the spinosad profile page.

Generic name: midostaurin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RYDAPT is a drug marketed by Novartis. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in twenty-seven countries. There has been litigation on patents covering RYDAPT

See drug price trends for RYDAPT.

The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this generic product. Additional details are available on the midostaurin profile page.

Generic name: cupric sulfate; manganese sulfate; selenious acid; zinc sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRALEMENT is a drug marketed by Am Regent.

This drug has sixty-two patent family members in twenty-seven countries.

See drug price trends for TRALEMENT.

The generic ingredient in TRALEMENT is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this generic product. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

Generic name: edaravone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RADICAVA is a drug marketed by Mitsubishi Tanabe. There are three patents protecting this drug.

This drug has sixty-two patent family members in twenty-seven countries.

See drug price trends for RADICAVA.

The generic ingredient in RADICAVA is edaravone. One supplier is listed for this generic product. Additional details are available on the edaravone profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2024
Generic Entry Controlled by: United States Patent Patent 7,084,245

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: United States Patent Patent 10,238,640

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GLEOLAN is a drug marketed by Nxdc.

This drug has nine patent family members in eight countries.

See drug price trends for GLEOLAN.

The generic ingredient in GLEOLAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2024
Generic Entry Controlled by: United States Patent Patent 7,947,295

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: bremelanotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYLEESI (AUTOINJECTOR) is a drug marketed by Palatin Technologies. There are four patents protecting this drug.

This drug has seventy-nine patent family members in twenty-five countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this generic product. Additional details are available on the bremelanotide acetate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: l-glutamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ENDARI is a drug marketed by Emmaus Medcl. One tentatively approved generic is ready to enter the market.

This drug has forty-six patent family members in thirty-one countries.

See drug price trends for ENDARI.

The generic ingredient in ENDARI is l-glutamine. There are forty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the l-glutamine profile page.

Generic name: dalbavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DALVANCE is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has fifty-eight patent family members in twenty countries.

See drug price trends for DALVANCE.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the dalbavancin hydrochloride profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KIMYRSA is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for KIMYRSA.

The generic ingredient in KIMYRSA is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ORBACTIV is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for ORBACTIV.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.